PT36. - HYPERTRIGLYCERIDEMIA IS A DOSE-DEPENDENT RISK FACTOR FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
PT36.
HYPERTRIGLYCERIDEMIA IS A DOSE-DEPENDENT RISK FACTOR FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
L. Havelda1,2,*, E. Á. Szalai1,3, M. Obeidat1, D. Dobszai1,4, D. S. Veres1,5, T. Kói1, E. Sipter1,6, S. Váncsa1,2, P. J. Hegyi1,2, M. Bucur1, A. Molnár1, K. L. Vámossy1,2, P. Hegyi1,2,4,7, A. Szentesi1,4
1Centre for Translational Medicine, Semmelweis University, 2Institute of Pancreatic Diseases, Semmelweis University, 3Department of Restorative Dentistry and Endodontics, Semmelweis University, Budapest, 4Institute for Translational Medicine, Medical School, University of Pécs, Pécs, 5Department of Biophysics and Radiation Biology, 6Department of Internal Medicine and Haematology, Semmelweis University, Budapest, 7Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary
Rationale: The prevalence of type 2 diabetes (T2DM) has more than doubled in the past 20 years and most of these T2DM cases are preventable if risk factors are eliminated in time. Hypertriglyceridemia (HTG) may be a potential but modifiable risk factor of T2DM, and it also has a high prevalence. We aimed to investigate the dose-dependent effect of HTG on the development of T2DM.
Methods: We carried out a systematic search in three databases (MEDLINE, Embase, and CENTRAL) on the 9th of November, 2023. We investigated adult population with different triglyceride levels and triglyceride-related indexes (exposure). The outcome of interest was the development of T2DM. Pooled hazard (HR), odds ratios (OR) and mean differences (MD) with 95% confidence intervals (CI) were calculated using a random-effect model. The risk of bias was assessed with the Quality In Prognosis Studies (QUIPS) tool. The protocol was registered in PROSPERO under the number CRD42023471288.
Results: We identified 31,098 articles and included 101 in our meta-analysis. We found that those who had HTG had more than a 1.5-fold higher risk (HR: 1.73 [1.31;2.29]) of the development of T2DM. Those who had their TG level between 1.7-2.3 mmol/L had a 42% higher risk (HR: 1.42 [1.13; 1.79]), while those who had a TG level above 2.3 mmol/L had an even higher risk for T2DM (HR: 1.82 [1.18; 2.87]) compared with patients with TG levels below 1.7 mmol/L. When investigating hypertriglyceridemic-waist phenotype, from the different phenotype groups, only those with increased waist circumference had a significantly higher risk in both sex groups (female: HR: 2.86 [1.59; 5.14], male: HR: 3.31 [1.57.7.27]).
Conclusion: HTG is a dose-dependent risk factor of T2DM. Elevated waist circumference may have an even more important role in T2DM development than HTG.
Disclosure of Interest: None declared